Objective: This study aimed to investigate the frequency in which familial Mediterranean fever (FMF) coexists with other diseases and determine whether Mediterranean fever (MEFV) gene mutations are involved in such coexistence.
Introduction
Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized by recurrent serositis and fever attacks. The disease is caused by mutations in a gene named Mediterranean fever (MEFV), which encodes a protein called pyrin. This protein is likely to have a downregulating influence on the response of neutrophils to inflammatory stimuli (1) .
It has been suggested that MEFV mutations facilitate a heightened inflammatory response that may be beneficial against a microorganism or a specific organism (2) . Nonetheless, it has been suggested that enhanced inflammation could predispose patients with FMF to some chronic inflammatory conditions. Some inflammatory disorders, including Henoch-Schonlein purpura (HSP), polyarteritis nodosa (PAN), Behcet's disease (BD), inflammatory bowel diseases, and multiple sclerosis, are also widely observed in FMF (3) . MEFV mutation modifies not only the clinical presentation of FMF but also other inflammatory disorders. However, the role of MEFV mutations in FMF co-existing with other inflammatory disorders remains to be ascertained. This study aimed to investigate the frequency in which FMF coexists with other diseases and to determine whether MEFV mutations are involved in such coexistence.
Material and Methods

Patients
In total, 142 consecutive patients with FMF investigated for MEFV mutation were enrolled in this study [Female: 87; Male: 55, mean age 32±12 years ]. They were diagnosed on the basis of the Tel-Hashomer diagnostic criteria (4). The study was approved by the local ethics committee. All patients provided informed consent to participate in the study, according to the guidelines of the Declaration of Helsinki. All the patients were questioned for the presence of concurrent disorders, and the medical records of these 
Results
In total, 129 of the 142 patients with FMF had positive mutation for MEFV gene (90.8%), but 13 of them showed no such mutation (9.2%) ( (Table 2 ).
There was a significant difference between Groups I and II in the frequency of arthritis and erysipela-like erythema (ELE) (p<0.01 and p<0.001, respectively).
No significant difference was found between Groups I and II in the frequency of fever, abdominal pain, and pleuritic pain (p>0.05). The number of patients with a higher severity score was significantly higher in Group I (12.9%) than in Group II (4.3%) (p<0.01). No significant differences could be found between Groups I and II in the number of patients with mild and moderate severity scores (p>0.05)
The rate of the familial history for FMF showed no significant difference in Groups I and II (63% vs. 57%, p=0.5).
Discussion
It has been reported that upregulation of the acute phase response among carriers of FMF may enhance their innate immune system and contribute to better resistance to infections (6) . On the other hand, in patients with FMF, there is a subclinical inflammation even during attack-free periods, and this continued inflammation conferred by inflammatory response may predispose patients with FMF to other inflammatory disorders such as PAN and HSP (7, 8) . It is well known that the presence of M694V allele gives rise to severe disease and amyloidosis in FMF. However, the role of M694V mutations in the development of concurrent disorders in the course of FMF is not well known. Kalyoncu et al. (9) showed that patients who are carriers for MEFV mutations may have a tendency to develop musculoskeletal rheumatologic complaints. Moreover the presence of these mutations may affect their disease course when they develop other rheumatic diseases.
We included Group I patients having only M694V allele (homozygote or heterozygote) to form a homogenous group. The patients with compound heterozygosity for M694V were added to Group II. We considered that this stratification may be a better way to determine whether M694V mutations play a role in concurrent disorders seen in patients with FMF. In line with the literature, the patients with M694V mutations had a severe disease score. Arthritis and ELE were more commonly determined in Group I. Seventeen patients having M694V mutations had concurrent disorders.
The most common concurrent disorder apart from amyloidosis in patients with FMF was AS. Six of 142 patients with FMF (4.2%) had AS. The frequency of AS in Group I was 6.8%. In Group II, AS was found at a frequency of 1.7%. We have previously that 7.3 of 256 patients with FMF had sacroiliitis, which was related to the presence of M694V mutations (10). Akar et al. (11) showed that patients with FMF having sacroiliitis more commonly had M694V mutation compared than those without sacroiliitis.
Kaşifoğlu et al. (12) reported that 8.6% of 2296 Turkish patients with FMF had amyloidosis and amyloidosis was associated with male gender, arthritis, and the presence of M694V genotype. We detected amyloidosis in 9 of 142 (6.3%) patients with FMF.
While amyloidosis was determined only 1 case with FMF in Group II (1.78%), the frequency of amyloidosis in Group I was found to be 10.9%.
The relationship between BD and FMF has been debatable for a long time. Chetrit et al. (13) found 2 patients with BD among 355 patients with FMF and 2 patients with FMF among 53 patients with BD. Sixteen patients with BD were found to have MEFV mutations, and 2 of them had FMF. Based on these results, they suggested that the association between BD-FMF was higher than expected in both directions. However, the small number of patients was a matter of concern in this study. Bakkaloğlu et al. (14) evaluated the presence of associate diseases in 2838 Turkish patients with FMF, and BD was found in 0.5% of patients with FMF. In our study, in Group I, we found 2 patients with FMF accompanied by BD, which is little high compared with the number reported in the literature. In Group II, only one patient with FMF had BD.
It is well known that the presence of MEFV mutation in cases without FMF can modify clinical manifestations of that disease. Atagündüz et al. (15) showed that there is a tendency to develop vascular involvement in BD patients with MEFV mutation.
The association of PAN and HSP with FMF is well known. The prevalence of HSP and PAN in Turkish patients with FMF has been found to be 7% and 1%, respectively (15) . The prevalence of HSP in the general population has been found to vary from 0.05% to 0.8% (8, 16 Bias is inevitable in our study because the presence of concomitant disorders significantly increases the chance of a disease being detected (Berkon's bias). The inclusion of disease controls in concurrence studies minimizes the impact of this important bias at least to some degree (19) . We could not include a disease control group in this study because of financial problems. The other limitation is that we formed Group 1 from only patients with FMF having homozygosity and heterozygosity for M694V. Compound heterozygosity for M694V was included in Group II. This categorization was made to form a homogenous group.
In conclusion, compared with FMF patients with other mutations, concurrent disorders were frequently determined in patients with FMF having M694V mutations and its subgroups. The patients with M694V mutation and its subgroups (homozygous, heterozygous) more commonly had arthritis, ELE, and a higher severe severity score than those with other mutations. MEFV mutations, particularly M694V mutations, can modify both clinical manifestations of FMF itself and those of other inflammatory disorders. The presence of M694V mutation in addition to other genetic and environmental factors may predispose FMF patients to developing other inflammatory disorders.
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